PTPRK and colonic neoplasm: In the present study, we have found for the first time that shRNA‐mediated knockdown of PTPRK significantly augments tumor growth and markedly reduces the anti‐cancer drug oxaliplatin sensitivity of CD133‐expressing colon cancer cells.